Results 51 to 60 of about 82,696 (289)

The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?

Cancer Management and Research, 2021
Michael Patrick Lux, 1 Oriana Ciani, 2 William CN Dunlop, 3 Andrea Ferris, 4 Michael Friedlander 5 1Department of Gynecology and Obstetrics, Frauenklinik St. Louise Paderborn, St. Josefs-Krankenhaus Salzkotten, Frauen- und Kinderklinik St.
Lux MP, Ciani O, Dunlop WCN, Ferris A, Friedlander M   +4 more
doaj  

Interferon β-1a in relapsing multiple sclerosis: four-year extension of the European IFNβ-1a Dose-C omparison Study [PDF]

, 2004
Background: Multiple sclerosis (MS) is a chronic disease requiring long-term monitoring of treatment. Objective: To assess the four-year clinical efficacy of intramuscular (IM) IFNb-1a in patients with relapsing MS from the European IFNb-1a Dose-C ...
Achiti, J., Arbizu, T., Arnulf, I., Aubertin, P., Bamborschke, P., Belliard, S., Berger, E., Blanc, S., Brassat, D., Brochet, B., Cahagne, V., Casado, A., Cesaro, P., Chan, A., Clanet, M., Confavreux, C., Dalecky, A., Damier, P., de Keyser, Jacques, de Marco, A., Defer, G., Degos, F., Dengler, R., Dose, A., Edan, G., Engles, A., Fernandez, O., Flachenecker, A., Gayou, A., Gelderblom, H., Grunwald, F., Grupe, A., Hartung, H.P., Heesen, C., Heidenreich, F., Heinzlef, O., Hohlfeld, R., Kappos, L., Kassim, N., Koehler, A., Koerner, A., Kristoferitsch, W., Kunze, K., Kyriallis, K., Lau, G., Lecanuet, P., Lindert, A., Liu, A., Lubetzki, C., Luenemann, J., Lyon-Caen, O., Magnier, C., Martin, A, Martinez-Yelamos, A., Matzke, A., Maurer, A., Mekies, C., Menck, A., Montalban, X., Moulin, A., Nolden, A., Nos, A., Pantzaris, A., Papacostas, S., Pelletier, J., Petereit, H., Pez, D., Piette, A., Riche, G., Rieckmann, P., Romero, F., Rouanet, M., Rouant, F., Roullet, E., Rumbach, L., Sailer, 27449, Schaeffer, S., Schlederer, A., Schrieber, A., Seeldrayers, P., Senard, A., Stankoff, B., Steiner, A., Stingle, A., Storch-Hagenlocher, A., Storch-Hagenlocher, B., Suchet, L., Tamayo, J.A., Tamman, D., Thalamas, C., Vermersch, P., Vogt-Schaden, A., Vuilleman, C., Weilbach, A., Weiler, C., Windhagen, A., Zorgdrager, A., Zschenderlein, R., Zwanniken, G.   +98 more
core   +1 more source

Linked dimers of the AAA+ ATPase Msp1 reveal energetic demands and mechanistic plasticity for substrate extraction from lipid bilayers

FEBS Letters, EarlyView.
Cells must clear mislocalized or faulty proteins from membranes to survive. The AAA+ ATPase Msp1 performs this task, but dissecting how its six subunits work together is challenging. We engineered linked dimers with varied numbers of functional subunits to reveal how Msp1 subunits cooperate and use energy to extract proteins from the lipid bilayer ...
Deepika Gaur, Brian Acquaviva, Baylee A. Smith, Nathan Walker, Isabella Walter, Matthew L. Wohlever   +5 more
wiley   +1 more source

CCT4 promotes tunneling nanotube formation

FEBS Letters, EarlyView.
Tunneling nanotubes (TNTs) are membranous tunnel‐like structures that transport molecules and organelles between cells. They vary in thickness, and thick nanotubes often contain microtubules in addition to actin fibers. We found that cells expressing monomeric CCT4 generate many thick TNTs with tubulin.
Miyu Enomoto, Akiko Asada, Taro Saito, Kanae Ando   +3 more
wiley   +1 more source

Surrogate endpoints in trials: a call for better reporting

Trials, 2022
Using a surrogate endpoint as a substitute for a patient-relevant final outcome enables randomised controlled trials (RCTs) to be conducted more efficiently. However, the use of surrogates remains controversial and there is currently no guideline for the
Oriana Ciani, Anthony M. Manyara, An-Wen Chan, Rod S. Taylor, on behalf of the SPIRIT-SURROGATE/CONSORT-SURROGATE project group   +4 more
doaj   +1 more source

Discussion of `Causation and Graphical Models? [PDF]

, 2003
C
Vansteelandt, Stijn
core   +1 more source

Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A phase 2, randomized, sham-controlled trial [PDF]

, 2018
Background -In non-randomized, open-label studies, a transcatheter interatrial shunt device (IASD, Corvia Medical) was associated with lower pulmonary capillary wedge pressure (PCWP), less symptoms, and greater quality of life and exercise capacity in ...
Basuray, Anupam, Burkhoff, Daniel, Fail, Peter S., Feldman, Ted, Forde-McLean, Rhondalyn, Hummel, Scott L., Kahwash, Rami, Kaye, David M., Lilly, Scott, Litwin, Sheldon, Massaro, Joseph M., Mauri, Laura, Nielsen, Christopher D., Penicka, Martin, Petrie, Mark C., Ricciardi, Mark J., Shah, Sanjiv J., van der Harst, Pim   +17 more
core   +1 more source

The anti‐CRISPR protein AcrIE8.1 inhibits the type I‐E CRISPR‐Cas system by directly binding to the Cascade subunit Cas11

FEBS Letters, EarlyView.
In this study, we present the structure of AcrIE8.1, a previously uncharacterized anti‐CRISPR protein that inhibits the type I‐E CRISPR‐Cas system. Through a combination of structural and biochemical analyses, we demonstrate that AcrIE8.1 directly binds to the Cas11 subunit of the Cascade complex to inhibit the CRISPR‐Cas system.
Young Woo Kang, Hyun Ho Park
wiley   +1 more source

How to use frailtypack for validating failure-time surrogate endpoints using individual patient data from meta-analyses of randomized controlled trials.

PLoS ONE, 2020
BACKGROUND AND OBJECTIVE:The use of valid surrogate endpoints can accelerate the development of phase III trials. Numerous validation methods have been proposed with the most popular used in a context of meta-analyses, based on a two-step analysis ...
Casimir Ledoux Sofeu, Virginie Rondeau
doaj   +1 more source

Measurable Residual Disease Assessment in Multiple Myeloma: How Deep Is Enough?

Hemato, 2022
The introduction of new and more effective therapeutic options for Multiple Myeloma (MM) has significantly deepened and prolonged patients’ remission.
Joana Caetano, Filipa Barahona, Paulo Lúcio, Cristina João   +3 more
doaj   +1 more source